Author

Nina Mitchell

Observed name: N. Mitchell

Observed institutions: University Hospitals Birmingham NHS Foundation Trust, Queen Mary University of London, GlaxoSmithKline (United Kingdom), Guy's and St Thomas' NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Roche (United Kingdom), University College London, Imperial College London, BioMarin (United States)

OpenAlex ID: A5110170086

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A

2020 · K. John Pasi, Savita Rangarajan, et al. · New England Journal of Medicine · 449

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

2015 · Gerd R Burmester, William F Rigby, et al. · Annals of the Rheumatic Diseases · 194

Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A

2022 · Sylvia Fong, Bridget Yates, et al. · Nature Medicine · 124

Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A

2021 · K John Pasi, Michael Laffan, et al. · Haemophilia · 95

Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A

2020 · Brian R. Long, Philippe Veron, et al. · Molecular Therapy · 76

Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study

2020 · Christopher D Buckley, Jesus A Simón-Campos, et al. · The Lancet Rheumatology · 42

OP0041 Tocilizumab (TCZ) in Combination and Monotherapy Versus Methotrexate (MTX) in MTX-Naive Patients (PTS) with Early Rheumatoid Arthritis (RA): Clinical and Radiographic Outcomes from a Randomised, Placebo-Controlled Trial

2013 · G. Burmester, W. Rigby, et al. · Annals of the Rheumatic Diseases · 28

MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study

2020 · Mark C Genovese, Mario Berkowitz, et al. · The Lancet Rheumatology · 25

Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer

2021 · Krystal Sandza, Annie Clark, et al. · Gene Therapy · 7

A First-in-human Four-year Follow-up Study of Durable Therapeutic Efficacy and Safety of Aav Gene Therapy With Valoctocogene Roxaparvovec for Severe Hemophilia a

2020 · M.C. Ozelo, K.J. Pasi, et al. · Hematology Transfusion and Cell Therapy · 3

Op0228 Gsk3196165 an Investigational Anti-gm-csf Monoclonal Antibody, Improves Patient Reported Outcomes in a Phase Iib Study of Patients With Rheumatoid Arthritis (ra)

2019 · Chris Buckley, Jesus Simon Campos, et al. · Annals of the Rheumatic Diseases · 3

SAT0226 Tocilizumab (TCZ) as Combination Therapy and as Monotherapy VS Methotrexate (MTX) in MTX-Naive Patients with Early Rheumatoid Arthritis: Patient-Reported Outcomes (PROS) from A Randomized, Placebo-Controlled Trial

2014 · G. Burmester, R. Blanco, et al. · Annals of the Rheumatic Diseases · 1

Unilateral Trade Measures - CBAM and Its Compatibility with the Climate Framework

2026 · Lindsay Colgan, Paul Ibuzor, et al.

Human liver biopsies from people with hemophilia A who received factor VIII gene transfer with valoctocogene roxaparvovec (AAV5-hFVIII-SQ) show unremarkable histopathology and reveal interindividual variability in transgene production

2022 · Sylvia Fong, Bridget Yates, et al. · Journal of Hepatology

Works count: 14

Citation count: 1,047

H-index: 8

I10-index: 8